Tandem Diabetes Care (TNDM) Expected to Announce Earnings on Thursday

Tandem Diabetes Care (NASDAQ:TNDM) is projected to release its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Tandem Diabetes Care to announce earnings of ($0.34) per share and revenue of $254.99 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The company had revenue of $247.22 million during the quarter, compared to the consensus estimate of $240.41 million. During the same quarter last year, the firm earned ($0.66) earnings per share. The company’s revenue was up 5.5% on a year-over-year basis. On average, analysts expect Tandem Diabetes Care to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tandem Diabetes Care Price Performance

Shares of Tandem Diabetes Care stock opened at $18.59 on Thursday. The company has a quick ratio of 3.07, a current ratio of 3.58 and a debt-to-equity ratio of 4.54. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -13.28 and a beta of 1.58. The company has a 50-day simple moving average of $16.36 and a two-hundred day simple moving average of $18.92. Tandem Diabetes Care has a twelve month low of $9.98 and a twelve month high of $29.65.

Hedge Funds Weigh In On Tandem Diabetes Care

Institutional investors have recently made changes to their positions in the stock. Freestone Grove Partners LP acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at about $22,706,000. Goldman Sachs Group Inc. raised its stake in Tandem Diabetes Care by 17.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,683,400 shares of the medical device company’s stock worth $37,001,000 after buying an additional 252,028 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in Tandem Diabetes Care by 11.6% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,653,708 shares of the medical device company’s stock worth $36,349,000 after acquiring an additional 171,755 shares in the last quarter. Geode Capital Management LLC grew its stake in Tandem Diabetes Care by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 1,649,383 shares of the medical device company’s stock valued at $36,260,000 after acquiring an additional 51,102 shares during the period. Finally, First Light Asset Management LLC bought a new stake in shares of Tandem Diabetes Care during the fourth quarter valued at approximately $23,947,000.

Analyst Upgrades and Downgrades

TNDM has been the topic of several analyst reports. Benchmark initiated coverage on Tandem Diabetes Care in a report on Monday, May 11th. They set a “hold” rating on the stock. TD Cowen reaffirmed a “buy” rating and issued a $28.00 target price (up from $25.00) on shares of Tandem Diabetes Care in a report on Monday, April 20th. Truist Financial reissued a “buy” rating and issued a $31.00 price objective (down from $35.00) on shares of Tandem Diabetes Care in a research note on Monday, May 11th. Rothschild & Co Redburn set a $45.00 price target on shares of Tandem Diabetes Care in a report on Friday, April 24th. Finally, The Goldman Sachs Group set a $21.00 price objective on Tandem Diabetes Care in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Hold” and an average target price of $28.73.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.